Should I buy Bristol Myers Squibb (BMY) stock or is it too late?

Bristol Myers Squibb · Health Care · price $57

See the full Bristol Myers Squibb (BMY) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $41 (-28 %), call made on October 8, 2026, maturing on October 8, 2027 (6 d ago).

The 8 reliable analysts $71.50+26 %

The 5 other firms $64+13 %

How to read it: the 8 reliable firms are not filtered by optimism — 7 aim above the price, 1 below, hence their $71.50 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Bristol Myers Squibb

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Goldman Sachs	100 %	+29.4 %	5	$57 +1%
Jefferies	73 %	+18.8 %	11	$68 +20%
Barclays	100 %	+11.2 %	5	$75 +32%
Morgan Stanley	81 %	+10.0 %	16	$41 -28%
B of A Securities	60 %	+1.5 %	5	$66 +16%
JP Morgan	40 %	-0.1 %	5	$73 +29%
Citigroup	40 %	-3.2 %	5	$70 +24%
Truist Securities	20 %	-7.2 %	5	$70 +24%

In short — Should you invest in Bristol Myers Squibb? Is it too late, still worth it? Analysts are split (46% buy, median target $68, i.e. +20%), and the most reliable on BMY targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $68, i.e. +20% from the current price ($57).
The most reliable firm on BMY, Goldman Sachs (100% hit rate, 5 scored calls), targets $57 (call made on December 2, 2025, maturing on December 2, 2026) (+1%) in its most recent call.
5 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
Pays a dividend (4.4% yield) — regular income on top of potential upside.
Reasonable valuation (P/E ~12) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 6 are neutral and 1 is a sell.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on BMY

Median target $68 (+20%) · 13 ratings · Hold consensus

Strong Buy00%

Buy646%

Hold646%

Sell18%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Bristol Myers Squibb now?

We won't decide for you. The facts: 46% of analysts rate it a buy, median target $68 (+20%), and Goldman Sachs (most reliable on BMY, 100%) targets $57. Weigh that against valuation (P/E ~12). This is not personalized advice.

Is it too late to invest in Bristol Myers Squibb?

Not according to analysts: the median target ($68) is still +20% above the current price ($57) (most reliable on BMY: Goldman Sachs, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Bristol Myers Squibb still worth investing in?

It depends on the gap between the price ($57) and its estimated value: analysts target $68 on median (+20%), with 46% buys (most reliable on BMY: Goldman Sachs, 100%). Cross-check with their real reliability on BMY and the cautions above. Information, not advice.

What's the main risk in buying BMY?

The consensus is not unanimous: of 13 ratings, 6 are neutral and 1 is a sell.

→ Go deeper: the full Bristol Myers Squibb profile (consensus, analyst reliability, price target, performance).